Gender Male
LinkedIn View on LinkedIn
Peter Laivins is the Board Member, Independent Director at Genexine. He previously worked at Merrimack in October 2011 and is Project Leader for MM-398 (nanotherapeutic-liposomal irinotecan), in Phase 3 development for Advanced Pancreatic Cancer.
Prior to joining Merrimack, Mr. Laivins ran an independent consulting practice specializing in
Oncology and Neuroscience.
Mr. Laivins has also served as Vice President of Strategic Brand Management for ELAN BioPharmaceuticals.
Mr. Laivins began his career at Pfizer Canada, Inc. and held positions of ascending responsibility at Pfizer International, in New York, and culminating as Group Leader of Pfizer US Oncology Marketing.
Mr. Laivins holds an M.B.A. and a B.S. in Microbiology and Immunology from McGill University in Montreal, Canada.
